Get Details: First Stock to Potentially Accumulate Rs 7 Crore Long-term Wealth
Here is the latest financial fact sheet of Dr. Reddys. For more details, see the Dr. Reddys quarterly results and Dr. Reddys share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | 1.2 |
No. of shares | m | 165.71 |
% ch week | % | -1.5 |
% ch 1-mth | % | -10.8 |
% ch 12-mth | % | 42.9 |
52 week H/L | Rs | 5,514.7/2,497.6 |
No. of Mths Year Ending |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
12 Mar-20* |
5-Yr Chart Click to enlarge
|
---|
DR. REDDYS LAB EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 4,383 | 3,397 | 2,788 | 2,875 | 3,363 | |
Low | Rs | 2,750 | 2,560 | 1,902 | 1,888 | 2,352 | |
Sales per share (Unadj.) | Rs | 912.5 | 856.5 | 860.8 | 930.2 | 1,054.2 | |
Earnings per share (Unadj.) | Rs | 124.9 | 78.0 | 57.1 | 117.4 | 121.9 | |
Diluted earnings per share | Rs | 128.6 | 78.0 | 57.1 | 117.7 | 122.3 | |
Cash flow per share (Unadj.) | Rs | 179.9 | 139.9 | 122.0 | 185.8 | 190.2 | |
Dividends per share (Unadj.) | Rs | 20.00 | 20.00 | 20.00 | 20.00 | 25.00 | |
Adj. dividends per share | Rs | 20.59 | 20.00 | 20.02 | 20.04 | 25.07 | |
Dividend yield (eoy) | % | 0.6 | 0.7 | 0.9 | 0.8 | 0.9 | |
Book value per share (Unadj.) | Rs | 736.8 | 739.8 | 757.7 | 844.4 | 938.7 | |
Adj. book value per share | Rs | 758.5 | 740.0 | 758.7 | 846.3 | 941.3 | |
Shares outstanding (eoy) | m | 170.61 | 165.74 | 165.91 | 166.07 | 166.17 | |
Bonus/Rights/Conversions | ESOP | BB | ESOP | ESOP | ESOP | ||
Price / Sales ratio | x | 3.9 | 3.5 | 2.7 | 2.6 | 2.7 | |
Avg P/E ratio | x | 28.6 | 38.2 | 41.1 | 20.3 | 23.4 | |
P/CF ratio (eoy) | x | 19.8 | 21.3 | 19.2 | 12.8 | 15.0 | |
Price / Book Value ratio | x | 4.8 | 4.0 | 3.1 | 2.8 | 3.0 | |
Dividend payout | % | 16.0 | 25.7 | 35.0 | 17.0 | 20.5 | |
Avg Mkt Cap | Rs m | 608,481 | 493,632 | 389,034 | 395,496 | 474,831 | |
No. of employees | `000 | 21.7 | 22.7 | 23.5 | 22.0 | 21.7 | |
Total wages/salary | Rs m | 31,174 | 31,068 | 32,149 | 33,562 | 33,802 | |
Avg. sales/employee | Rs Th | 7,184.6 | 6,259.0 | 6,070.8 | 7,032.8 | 8,091.0 | |
Avg. wages/employee | Rs Th | 1,438.6 | 1,369.8 | 1,366.6 | 1,527.9 | 1,561.3 | |
Avg. net profit/employee | Rs Th | 983.2 | 569.7 | 402.5 | 887.7 | 935.8 |
DR. REDDYS LAB INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 155,683 | 141,961 | 142,810 | 154,482 | 175,170 | |
Other income | Rs m | 2,950 | 1,715 | 1,552 | 3,375 | 6,206 | |
Total revenues | Rs m | 158,633 | 143,676 | 144,362 | 157,857 | 181,376 | |
Gross profit | Rs m | 35,853 | 24,722 | 23,512 | 31,782 | 24,421 | |
Depreciation | Rs m | 9,389 | 10,266 | 10,772 | 11,348 | 11,348 | |
Interest | Rs m | 826 | 634 | 788 | 889 | 983 | |
Profit before tax | Rs m | 28,588 | 15,537 | 13,504 | 22,920 | 18,296 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 229 | 349 | 344 | 438 | 561 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 7,511 | 2,965 | 4,380 | 3,858 | -1,403 | |
Profit after tax | Rs m | 21,306 | 12,921 | 9,468 | 19,500 | 20,260 | |
Gross profit margin | % | 23.0 | 17.4 | 16.5 | 20.6 | 13.9 | |
Effective tax rate | % | 26.3 | 19.1 | 32.4 | 16.8 | -7.7 | |
Net profit margin | % | 13.7 | 9.1 | 6.6 | 12.6 | 11.6 |
DR. REDDYS LAB BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 117,940 | 96,837 | 104,984 | 111,101 | 125,991 | |
Current liabilities | Rs m | 63,471 | 84,199 | 68,938 | 58,973 | 72,141 | |
Net working cap to sales | % | 35.0 | 8.9 | 25.2 | 33.7 | 30.7 | |
Current ratio | x | 1.9 | 1.2 | 1.5 | 1.9 | 1.7 | |
Inventory Days | Days | 60 | 73 | 74 | 79 | 73 | |
Debtors Days | Days | 97 | 98 | 104 | 94 | 105 | |
Net fixed assets | Rs m | 73,352 | 102,552 | 104,385 | 101,245 | 83,854 | |
Share capital | Rs m | 853 | 829 | 830 | 830 | 831 | |
"Free" reserves | Rs m | 124,845 | 121,792 | 124,886 | 139,406 | 155,157 | |
Net worth | Rs m | 125,698 | 122,621 | 125,716 | 140,236 | 155,988 | |
Long term debt | Rs m | 10,685 | 5,449 | 25,089 | 22,000 | 1,304 | |
Total assets | Rs m | 203,841 | 218,165 | 225,443 | 224,656 | 232,253 | |
Interest coverage | x | 35.6 | 25.5 | 18.1 | 26.8 | 19.6 | |
Debt to equity ratio | x | 0.1 | 0 | 0.2 | 0.2 | 0 | |
Sales to assets ratio | x | 0.8 | 0.7 | 0.6 | 0.7 | 0.8 | |
Return on assets | % | 10.9 | 6.2 | 4.5 | 9.1 | 9.1 | |
Return on equity | % | 17.0 | 10.5 | 7.5 | 13.9 | 13.0 | |
Return on capital | % | 21.7 | 12.9 | 9.7 | 14.9 | 12.6 | |
Exports to sales | % | 46.6 | 54.6 | 0 | 0 | 0 | |
Imports to sales | % | 9.0 | 9.4 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 72,618 | 77,520 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 14,050 | 13,274 | 0 | 0 | 0 | |
Fx inflow | Rs m | 75,405 | 81,670 | 72,623 | 88,673 | 84,193 | |
Fx outflow | Rs m | 27,115 | 26,355 | 18,916 | 19,104 | 39,616 | |
Net fx | Rs m | 48,290 | 55,315 | 53,707 | 69,569 | 44,577 |
DR. REDDYS LAB CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | 32,626 | 21,444 | 18,030 | 28,704 | 29,841 | |
From Investments | Rs m | -20,394 | -18,404 | -14,883 | -7,727 | -4,923 | |
From Financial Activity | Rs m | -17,001 | -3,692 | -4,440 | -21,326 | -25,159 | |
Net Cashflow | Rs m | -474 | -1,144 | -1,236 | -314 | -266 |
Share Holding
|
Company Information
|
CHM: G. V. Prasad | COMP SEC: Sandeep Poddar | YEAR OF INC: 1984 | BSE CODE: 500124 | FV (Rs): 5 | DIV YIELD (%): 0.6 |
More Pharmaceuticals Company Fact Sheets: AMAR REMEDIES ALEMBIC SUN PHARMA CIPLA AJANTA PHARMA
Compare DR. REDDYS LAB With: AMAR REMEDIES ALEMBIC SUN PHARMA CIPLA AJANTA PHARMA
Compare DR. REDDYS LAB With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Asian stock markets opened sharply lower today after Wall Street's main indexes tumbled, with technology-related stocks under pressure following a steep rise in benchmark US Treasury yields.
In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More